Suppr超能文献

危重症患者肾上腺功能不全的诊断与治疗

Diagnosis and treatment of adrenal insufficiency in the critically ill patient.

作者信息

Asare Kwame

机构信息

Pharmacy Department, St. Thomas Hospital, 4220 Harding Road, Nashville, TN 37202, USA.

出版信息

Pharmacotherapy. 2007 Nov;27(11):1512-28. doi: 10.1592/phco.27.11.1512.

Abstract

The reported incidence of adrenal insufficiency varies greatly depending on the population of critically ill patients studied, the test and cutoff levels used, and the severity of illness. Several studies have shown increased mortality in patients with very low or very high baseline cortisol levels. Manifestations of adrenal insufficiency in the critically ill patient are numerous and nonspecific, so clinicians are urged to have a high index of suspicion and be alert to important diagnostic clues, such as hyponatremia, hyperkalemia, and hypotension, that are refractory to fluids and vasopressors without any clear causation. Multiple tests have been developed to diagnose adrenal insufficiency, but the most commonly used test in the intensive care unit is the adrenocorticotropic hormone (ACTH) stimulation test. The low-dose ACTH stimulation test has been shown to be more sensitive and specific than the high-dose test; however, the high-dose test is preferred since the low-dose test has not been validated. Although diagnosing adrenal insufficiency continues to be difficult in the critically ill patient, administration of high-dose corticosteroids, defined as methylprednisolone 30 mg/kg/day or more (or its equivalent), over a short period of time provides no overall benefit and may even be harmful; however, administration of low-dose corticosteroids for a longer duration decreases both the amount of the time that vasopressors are required and mortality at 28 days. Hydrocortisone 200-300 mg/day, administered in divided doses or as a continuous infusion, is the preferred corticosteroid in patients with septic shock and should be started as early as possible. For patients in whom the ACTH stimulation test cannot be given immediately, clinicians are urged to consider using dexamethasone until such time that the test can be administered, since, unlike hydrocortisone, it does not interfere with the cortisol test.

摘要

肾上腺功能不全的报告发病率因所研究的危重症患者群体、所用检测方法和临界值水平以及疾病严重程度的不同而有很大差异。多项研究表明,基线皮质醇水平极低或极高的患者死亡率增加。危重症患者肾上腺功能不全的表现多种多样且缺乏特异性,因此敦促临床医生保持高度怀疑,并警惕重要的诊断线索,如低钠血症、高钾血症和低血压,这些情况在没有明确病因的情况下对液体和血管升压药治疗无效。已经开发了多种检测方法来诊断肾上腺功能不全,但重症监护病房最常用的检测方法是促肾上腺皮质激素(ACTH)刺激试验。低剂量ACTH刺激试验已被证明比高剂量试验更敏感和特异;然而,由于低剂量试验尚未得到验证,高剂量试验更受青睐。尽管在危重症患者中诊断肾上腺功能不全仍然困难,但在短时间内给予高剂量皮质类固醇(定义为甲泼尼龙30mg/kg/天或更高剂量,或其等效剂量)并无总体益处,甚至可能有害;然而,长时间给予低剂量皮质类固醇可减少血管升压药的使用时间,并降低28天死亡率。氢化可的松200 - 300mg/天,分剂量给药或持续输注,是感染性休克患者首选的皮质类固醇,应尽早开始使用。对于不能立即进行ACTH刺激试验的患者,敦促临床医生考虑使用地塞米松,直到可以进行该试验,因为与氢化可的松不同,它不会干扰皮质醇检测。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验